Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01045083 · ClinicalTrials.gov registry record · Phase 1
A Study of the Ability of Functional Magnetic Resonance Imaging (fMRI) to Detect and Characterize the Effects of Two Marketed Centrally Active Drugs, Placebo, and RO4917523 in Healthy Volunteers
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT01045083 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 25 participants.
The verdict
NCT01045083, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is an exploratory study to evaluate the usefulness of fMRI as a biomarker to characterize the response to three centrally active drugs and placebo.
Interventions
- DRUG placebo
- DRUG methylphenidate
- DRUG escitalopram
- DRUG RO4917523
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2010-01 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01045083
The ClinicalTrials.gov registry entry for NCT01045083 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT01045083 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01045083 about?
NCT01045083 is a clinical study titled "A Study of the Ability of Functional Magnetic Resonance Imaging (fMRI) to Detect and Characterize the Effects of Two Marketed Centrally Active Drugs, Placebo, and RO4917523 in Healthy Volunteers". This is an exploratory study to evaluate the usefulness of fMRI as a biomarker to characterize the response to three centrally active drugs and placebo.
What is the current status of trial NCT01045083?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2010-01. Estimated completion is 2011-06.
What interventions are being tested in trial NCT01045083?
The interventions under investigation include: placebo (DRUG), methylphenidate (DRUG), escitalopram (DRUG), RO4917523 (DRUG).
Who is sponsoring clinical trial NCT01045083?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.